FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma

The Food and Drug Administration approved belzutifan, or Welireg, marketed by Merck (MRK), for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, or PPGL. “This represents the first FDA approval of an oral therapy for PPGL,” the FDA stated.